Evogene Ltd.
1.52
-0.03 (-1.94%)
At close: Jan 14, 2025, 3:48 PM
1.52
0.00%
After-hours Jan 14, 2025, 03:48 PM EST
undefined%
Bid 1.5
Market Cap 8.16M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -4.4
PE Ratio (ttm) -0.35
Forward PE n/a
Analyst Buy
Ask 1.57
Volume 13,925
Avg. Volume (20D) 308,659
Open 1.58
Previous Close 1.55
Day's Range 1.50 - 1.61
52-Week Range 1.20 - 10.40
Beta undefined

About EVGN

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 15, 2010
Employees 142
Stock Exchange NASDAQ
Ticker Symbol EVGN

Analyst Forecast

According to 1 analyst ratings, the average rating for EVGN stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 689.47% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Evogene Ltd. is scheduled to release its earnings on Mar 6, 2025, before market opens.
Analysts project revenue of $3.62M, reflecting a 526.30% YoY growth and earnings per share of -0.73, making a -43.85% decrease YoY.
3 months ago · Source
+19.92%
Evogene shares are trading higher after the compan... Unlock content with Pro Subscription
4 months ago · Source
-10.8%
Evogene shares are trading lower after the company reported worse-than-expected Q2 EPS results.